Brazil's National Health Regulatory Agency (Anvisa) has given the nod to the country's first injectable HIV prevention drug, Cabotegravir.Although its approval was announced in the Official Journal of the Union (DOU) on June 5, the timeline for its market availability remains undetermined.This breakthrough medication is classified as a pre-exposure prophylaxis (PrEP), designed to avert potential HIV infections.Given the absence of a vaccine against the virus, this injectable PrEP signifies a significant advancement in HIV prevention.The United States Food and Drug Administration (FDA) approved Cabotegravir in 2021, followed by an endorsement from the World ..To read the full NEWS and much more, Subscribe to our Premium Membership Plan.
Already Subscribed? Login Here